Ryuya Hashimoto1, Meizi Jiang2, Tomoaki Shiba3, Nobuyuki Hiruta2, Mao Takahashi4, Morihiro Higashi5, Yuichi Hori3, Hideaki Bujo6, Takatoshi Maeno1. 1. Department of Ophthalmology, Sakura Medical Center of Toho University, 564-1, Shimoshizu, Sakura, 285-8741, Japan. 2. Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-Shi, Chiba prefecture, 285-8741, Japan. 3. Department of Ophthalmology, Toho University Omori Medical Center, Tokyo, 143-8541, Japan. 4. Cardiovascular Center, Toho University Sakura Medical Center, Sakura, 285-8741, Japan. 5. Department of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, 350-8550, Japan. 6. Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura-Shi, Chiba prefecture, 285-8741, Japan. hideaki.bujo@med.toho-u.ac.jp.
Abstract
PURPOSE: LR11 (also called SorLA or SORL1) is a migration regulator of adherent cells with the immature proliferative phenotype. The present study investigated the clinical and pathological involvement of the soluble form of LR11 (sLR11) in the idiopathic epiretinal membrane (iERM). METHODS: The subjects were 51 patients with iERM (24 cellophane macular reflex (CMR) and 27 preretinal macular fibrosis (PMF)) and 45 patients with macular holes as age and sex-matched controls. Vitreous sLR11 and transforming growth factor (TGF)β2 levels were measured by ELISA. RESULTS: The sLR11 levels in the vitreous fluids of patients with iERM (20.2 ± 8.1 ng/mL) were significantly higher than those in controls (11.4 ± 4.7 ng/mL). Among the patients with iERM, the vitreous sLR11 levels were significantly higher in PMF (23.6 ± 8.2 ng/mL), than those in CMR (16.5 ± 5.9 ng/mL). Multivariate regression analysis of the studied factors showed that sLR11 was a unique factor independently contributing to the discrimination of the iERM patients against the control subjects (odds ratio [OR] 1.35 per 1-ng/mL increase, 95% CI 1.09-1.67; P = 0.004). ROC analysis showed that the sensitivity and the specificity of sLR11, but not of other studied factors, categorized into the rank of moderate accuracy. Finally, there was a positive correlation (R = 0.588; P = 0.003) between the vitreous levels of sLR11 and TGFβ2 using the available samples. CONCLUSIONS: sLR11 levels in vitreous fluids were specifically increased in patients with iERM, suggesting the involvement in the pathology of proliferative and migrating cells for the development of iERM.
PURPOSE:LR11 (also called SorLA or SORL1) is a migration regulator of adherent cells with the immature proliferative phenotype. The present study investigated the clinical and pathological involvement of the soluble form of LR11 (sLR11) in the idiopathic epiretinal membrane (iERM). METHODS: The subjects were 51 patients with iERM (24 cellophane macular reflex (CMR) and 27 preretinal macular fibrosis (PMF)) and 45 patients with macular holes as age and sex-matched controls. Vitreous sLR11 and transforming growth factor (TGF)β2 levels were measured by ELISA. RESULTS: The sLR11 levels in the vitreous fluids of patients with iERM (20.2 ± 8.1 ng/mL) were significantly higher than those in controls (11.4 ± 4.7 ng/mL). Among the patients with iERM, the vitreous sLR11 levels were significantly higher in PMF (23.6 ± 8.2 ng/mL), than those in CMR (16.5 ± 5.9 ng/mL). Multivariate regression analysis of the studied factors showed that sLR11 was a unique factor independently contributing to the discrimination of the iERM patients against the control subjects (odds ratio [OR] 1.35 per 1-ng/mL increase, 95% CI 1.09-1.67; P = 0.004). ROC analysis showed that the sensitivity and the specificity of sLR11, but not of other studied factors, categorized into the rank of moderate accuracy. Finally, there was a positive correlation (R = 0.588; P = 0.003) between the vitreous levels of sLR11 and TGFβ2 using the available samples. CONCLUSIONS: sLR11 levels in vitreous fluids were specifically increased in patients with iERM, suggesting the involvement in the pathology of proliferative and migrating cells for the development of iERM.
Authors: S A Vinores; J D Henderer; J Mahlow; C Chiu; N L Derevjanik; W Larochelle; C Csaky; P A Campochiaro Journal: Exp Eye Res Date: 1995-06 Impact factor: 3.467
Authors: Laura Bianchi; Annalisa Altera; Virginia Barone; Denise Bonente; Tommaso Bacci; Elena De Benedetto; Luca Bini; Gian Marco Tosi; Federico Galvagni; Eugenio Bertelli Journal: Cells Date: 2022-08-15 Impact factor: 7.666